Annual report pursuant to Section 13 and 15(d)

Notes Payable (Narrative) (Details)

Notes Payable (Narrative) (Details)		1 Months Ended						6 Months Ended	12 Months Ended
Notes Payable (Narrative) (Details)	Jun. 25, 2013 USD ($) $ / shares shares	Jul. 31, 2015 USD ($)	May. 31, 2015 USD ($)	Jul. 31, 2014 USD ($)	Mar. 31, 2014 USD ($) $ / shares shares	Jun. 30, 2013 Installment shares	Jul. 31, 2012 USD ($)	Jun. 24, 2013 USD ($)	Dec. 31, 2015 USD ($) d $ / shares	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($) $ / shares shares	May. 15, 2015 USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt									$ 2,440,714	$ 2,610,196	$ 1,372,266
Shares conversion, number of common stock equivalent to each preferred stock \| shares						3,270
Repayments of notes payable		$ 333,333		$ 666,666					30,333,333	25,000,000	5,982,155
Change in fair value of financial instruments									(614,782)	(1,342,389)	(112,073)
Compounded interest on notes payable									2,048,960
Notes payable									$ 61,100,000	33,800,000
Exercise price of warrant issued, dollars per share \| $ / shares									$ 0.38
Notes payable, current									$ 333,333	4,348,678
Interest expense									6,900,000	3,700,000	2,800,000
Interest expense recorded related to amortization									493,000	844,000	765,000
Principal maturities in 2016									333,000
Principal maturities in 2017									0
Principal maturities in 2018									0
Principal maturities in 2019									21,900,000
Principal maturities in 2020									29,200,000
Principal maturities in 2021									26,500,000
R-NAV [Member]
Debt Instrument [Line Items]
Repayments of notes payable		$ 333,333
Notes payable, current									$ 333,333
Minimum [Member]
Debt Instrument [Line Items]
Exercise price of warrant issued, dollars per share \| $ / shares									$ 0.01
Federal Funds Rate [Member] \| R-NAV [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate				0.31%
Series B Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion of Series B preferred stock to common stock, shares \| shares						2,364.9
Series KK warrants [Member}
Debt Instrument [Line Items]
Exercise price of warrant issued, dollars per share \| $ / shares									1.918
Series HH Warrants [Member]
Debt Instrument [Line Items]
Number of shares underlying warrant issued \| shares						301,205
Exercise price of warrant issued, dollars per share \| $ / shares									2.49
Series GG Warrants [Member]
Debt Instrument [Line Items]
Exercise price of warrant issued, dollars per share \| $ / shares									$ 2.10
Platinum-Montaur Life Sciences LLC [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity, amount							$ 50,000,000		$ 50,000,000
Current borrowing capacity							35,000,000			35,000,000
Amount potentially available on terms to be negotiated							$ 15,000,000
Proceeds from lines of credit	$ 8,000,000								$ 4,500,000	0	$ 4,000,000
Debt Instrument, basis spread on variable rate											6.75%
Interest rate stated percentage rate range minimum					10.00%						10.00%
Interest rate in addition to amended agreement											0.125%
Percentage of VWAP for conversion calculation											90.00%
Period of preceding date of conversion request											10 days
Minimum revenue from sales and licensing for mandatory repayment due											$ 2,000,000
Loss on extinguishment of debt											943,000
Number of common shares underlying Series B Preferred Stock \| shares						7,733,223
Repayments of notes payable											4,800,000
Debt instrument, effective interest rate									14.125%
Convertible threshold trading days \| d									10
Share price trigger \| $ / shares									$ 2.53
Change in fair value of financial instruments									$ (615,000)	$ (1,300,000)	$ (106,000)
Platinum notes payable									11,500,000
Compounded interest on notes payable									761,000
Notes payable									8,500,000
Portion of outstanding balance resulting from draws									7,700,000
Remaining borrowing capacity									$ 27,300,000
Platinum-Montaur Life Sciences LLC [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate									10.00%
Platinum-Montaur Life Sciences LLC [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate					6.75%
Platinum-Montaur Life Sciences LLC [Member] \| Oxford Finance, LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate					0.125%
Platinum-Montaur Life Sciences LLC [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate									6.75%
Platinum-Montaur Life Sciences LLC [Member] \| Interest Rate Pursuant to CRG Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate									0.125%
Capital Royalty Partners II LP [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate			14.00%
Compounded interest on notes payable									$ 1,300,000
Notes payable									$ 51,300,000
Debt instrument face amount			$ 50,000,000
Debt Instrument, unused borrowing capacity			$ 10,000,000
Debt Instrument, interest rate, paid in cash			10.00%
Debt Instrument, Interest rate, paid-in-kind			4.00%
Debt instrument, frequency of payment									eight equal quarterly installments
Payment terms									2 years
Debt instrument, maturity date									Mar. 31, 2021
Notice period for prepayment of tem loan									15 days
Debt Instrument, Fee Amount														$ 625,000
End-of-term fee amount									$ 1,000,000					1,000,000
EBITDA, less than									5,000,000
Minimum sales revenue target in 2015									11,000,000
Minimum sales revenue target in 2016									$ 22,500,000
Minimum sales revenue target in 2020														45,000,000
Cure right ratio									2.50%
Minimum net revenue									$ 10,000,000
Liquidity minimum									5,000,000					5,000,000
Unamortized discount (premium), net														2,200,000
Notes payable, discounts									$ 2,000,000
Capital Royalty Partners II LP [Member] \| Prepayment Premium Initial [Member]
Debt Instrument [Line Items]
Early payment percentage									5.00%
Capital Royalty Partners II LP [Member] \| Prepayment Premium Declining [Member]
Debt Instrument [Line Items]
Early payment percentage									1.00%
Capital Royalty Partners II LP [Member] \| Prepayment Premium After Fifth Year [Member]
Debt Instrument [Line Items]
Early payment percentage									0.00%
Oxford Finance, LLC [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate					8.50%
Debt instrument face amount					$ 30,000,000
End-of-term fee amount					2,400,000									2,400,000
Unamortized discount (premium), net					3,000,000
Debt issuance costs					$ 120,000
Repayments of long-term debt			$ 31,700,000
Early redemption fee amount														$ 289,000
Oxford Finance, LLC [Member] \| Series KK warrants [Member}
Debt Instrument [Line Items]
Number of shares underlying warrant issued \| shares					391,032
Exercise price of warrant issued, dollars per share \| $ / shares					$ 1.918
Warrants expiration period									2021-03
GECC/MidCap Financial SBIC LP [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt					$ 2,600,000
Debt instrument, interest rate	9.83%
Debt instrument face amount	$ 25,000,000
Debt instrument, frequency of payment									monthly
End-of-term fee amount	1,000,000				1,000,000
Notes payable, discounts	1,900,000
Debt issuance costs	$ 881,000
Repayments of long-term debt					26,700,000
Early redemption fee amount					$ 500,000
Debt instrument, number of periodic installments \| Installment						30
Percentage of original principal amount of loan to be paid as a fee	4.00%
Debt instrument, carrying amount									$ 0
GECC/MidCap Financial SBIC LP [Member] \| Series HH Warrants [Member]
Debt Instrument [Line Items]
Number of shares underlying warrant issued \| shares	301,205
Exercise price of warrant issued, dollars per share \| $ / shares	$ 2.49
Warrants expiration period									2023-06
Hercules Technology II L.P. [Member]
Debt Instrument [Line Items]
Current borrowing capacity													$ 7,000,000
Loss on extinguishment of debt	$ 429,000
Repayments of notes payable	4,400,000							$ 1,300,000				$ 1,300,000
Notes payable, discounts	187,000
Debt instrument, end of term fee	250,000
Debt instrument, early payment penalty	66,000
Unamortized debt issuance expense	$ 176,000
Hercules Technology II L.P. [Member] \| Series GG Warrants [Member]
Debt Instrument [Line Items]
Number of shares underlying warrant issued \| shares													333,333
Exercise price of warrant issued, dollars per share \| $ / shares													$ 2.10
Warrants expiration period													2016-12